Tregs and gene regulation define Sangamo’s next act
Sangamo takes a second shot at a first mover advantage as it pivots from gene editing to engineering Treg cell therapies
More than 25 years into its story, pioneering gene editing company Sangamo is shifting gears to focus on a leadership opportunity in the emerging regulatory T cell therapy space, but the company is not abandoning its zinc finger protein roots.
The latest pivot by Sangamo Therapeutics Inc. (NASDAQ:SGMO) reflects the challenge of keeping pace when disruptive technologies threaten to displace a platform, and may prove an example of how to adapt by retooling and redirecting the technology to aim for a lead position in a less competitive space...
BCIQ Company Profiles
BCIQ Target Profiles